Search Results - "Omi Parikh"

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial by Parker, Christopher C, James, Nicholas D, Brawley, Christopher D, Clarke, Noel W, Hoyle, Alex P, Ali, Adnan, Ritchie, Alastair W S, Attard, Gerhardt, Chowdhury, Simon, Cross, William, Dearnaley, David P, Gillessen, Silke, Gilson, Clare, Jones, Robert J, Langley, Ruth E, Malik, Zafar I, Mason, Malcolm D, Matheson, David, Millman, Robin, Russell, J Martin, Thalmann, George N, Amos, Claire L, Alonzi, Roberto, Bahl, Amit, Birtle, Alison, Din, Omar, Douis, Hassan, Eswar, Chinnamani, Gale, Joanna, Gannon, Melissa R, Jonnada, Sai, Khaksar, Sara, Lester, Jason F, O'Sullivan, Joe M, Parikh, Omi A, Pedley, Ian D, Pudney, Delia M, Sheehan, Denise J, Srihari, Narayanan Nair, Tran, Anna T H, Parmar, Mahesh K B, Sydes, Matthew R

“…Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that…”
Get full text

Genomics of lethal prostate cancer at diagnosis and castration resistance by Mateo, Joaquin, Seed, George, Bertan, Claudia, Rescigno, Pasquale, Dolling, David, Figueiredo, Ines, Miranda, Susana, Nava Rodrigues, Daniel, Gurel, Bora, Clarke, Matthew, Atkin, Mark, Chandler, Rob, Messina, Carlo, Sumanasuriya, Semini, Bianchini, Diletta, Barrero, Maialen, Petermolo, Antonella, Zafeiriou, Zafeiris, Fontes, Mariane, Perez-Lopez, Raquel, Tunariu, Nina, Fulton, Ben, Jones, Robert, McGovern, Ursula, Ralph, Christy, Varughese, Mohini, Parikh, Omi, Jain, Suneil, Elliott, Tony, Sandhu, Shahneen, Porta, Nuria, Hall, Emma, Yuan, Wei, Carreira, Suzanne, de Bono, Johann S

“…The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary…”
Get full text

Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer (mCRPC): Results from an expanded access program by Thomson, David, Charnley, Natalie, Parikh, Omi

“…Abstract only 188 Background: Abiraterone or enzalutamide are licensed for use post-docetaxel in metastatic castrate resistant prostate cancer (mCRPC). Both…”
Get full text

Comparing Clinical Outcomes for Radium 223 – Do Older Patients Do Worse? by Song, Yee Pei, MB BCh., MRCP, Ellis, Tracey, BSc., MSc, Walshaw, Richard, MB ChB., MRCP., FRCR, Mbanu, Peter, MB ChB., MRCP, Parikh, Omi, BSc(Hons)., MB ChB(Hons)., MRCP., FRCR, Logue, John, MB ChB., MRCP., FRCR, Choudhury, Ananya, MA., PhD., MRCP., FRCR

“…Abstract Introduction Prostate cancer affects older men. Bone is a common site of metastatic disease in patients with castrate resistant prostate cancer…”
Get full text

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry by Bjartell, Anders, Costa, Luis, Kramer, Gero, Zurawski, Bogdan, Galli, Luca, Werbrouck, Patrick, Ecke, Thorsten, Parikh, Omi, Bennamoun, Mostefa, Garcia Freire, Camilo, Peer, Avivit, Ljungberg, Börje, Cicin, Irfan, Smith, Emma, Lukac, Martin, Wapenaar, Robert, Chowdhury, Simon

“…Patient characteristics appear to influence the first-line treatment of metastatic castration-resistant prostate cancer. Patients older and with lower Gleason…”
Get full text

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma by Oudard, Stephane, Benhamouda, Nadine, Escudier, Bernard, Ravel, Patrice, Tran, Thi, Levionnois, Emeline, Negrier, Sylvie, Barthelemy, Philippe, Berdah, Jean François, Gross-Goupil, Marine, Sternberg, Cora N, Bono, Petri, Porta, Camillo, De Giorgi, Ugo, Parikh, Omi, Hawkins, Robert, Highley, Martin, Wilke, Jochen, Decker, Thomas, Tanchot, Corinne, Gey, Alain, Terme, Magali, Tartour, Eric

“…The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1 CD14 and Tie2 CD14) was analyzed in an ancillary study from the prospective PazopanIb…”
Get full text

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib by Mitchell, Catherine C, Parikh, Omi A

“…The last decade has seen a surge in the treatment options for metastatic renal cell carcinoma and life expectancies are now approaching 3 years from diagnosis…”
Get full text

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study by Lindskog, Magnus, Laurell, Anna, Kjellman, Anders, Melichar, Bohuslav, Rey, Pablo Maroto, Zieliński, Henryk, Villacampa, Felipe, Bigot, Pierre, Zoltan, Bajory, Parikh, Omi, Alba, David Vazquez, Jellvert, Åsa, Flaskó, Tibor, Gallardo, Enrique, Caparrós, Maria José Ribal, Purkalne, Gunta, Suenaert, Peter, Karlsson-Parra, Alex, Ljungberg, Börje

“…Intratumoral injection of ilixadencel, consisting of proinflammatory allogeneic dendritic cells, before nephrectomy, followed by sunitinib treatment after…”
Get full text

Severe Thrombocytopenia Induced by a Single Infusion of Trastuzumab by Parikh, Omi, Neave, Farhad, Palmieri, Carlo

“…Abstract We report a case of severe thrombocytopenia related to adjuvant trastuzumab use. Less than 24 hours after administration of her first dose of…”
Get full text

Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography-The IP1-PROSTAGRAM Study by Oong, Zhu, Parikh, Omi

Get more information

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial by Mateo, Joaquin, Porta, Nuria, Bianchini, Diletta, McGovern, Ursula, Elliott, Tony, Jones, Robert, Syndikus, Isabel, Ralph, Christy, Jain, Suneil, Varughese, Mohini, Parikh, Omi, Crabb, Simon, Robinson, Angus, McLaren, Duncan, Birtle, Alison, Tanguay, Jacob, Miranda, Susana, Figueiredo, Ines, Seed, George, Bertan, Claudia, Flohr, Penny, Ebbs, Berni, Rescigno, Pasquale, Fowler, Gemma, Ferreira, Ana, Riisnaes, Ruth, Pereira, Rita, Curcean, Andra, Chandler, Robert, Clarke, Matthew, Gurel, Bora, Crespo, Mateus, Nava Rodrigues, Daniel, Sandhu, Shahneen, Espinasse, Aude, Chatfield, Peter, Tunariu, Nina, Yuan, Wei, Hall, Emma, Carreira, Suzanne, de Bono, Johann S

“…Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate…”
Get full text

Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer by Thomson, David, Charnley, Natalie, Parikh, Omi

Get full text

Patterns of early 18F-FDG PET response to nivolumab (NIVO) and ipilimumab nivolumab (IPINIVO) in patients with metastatic renal cancer (MRC) by Charnley, Natalie, Rosof-Wiliams, Diana, Dobson, Mike, Cox, Susan, Amin, Nisreen, Parikh, Omi, Thompson, Catherine, Danwata, Falalu Dahiru, Cain, John

“…374 Background: Immunotherapy with IPINIVO and NIVO is a standard treatment in MRC. This leads to recruitment and activation of immune cells. The ‘immune…”
Get full text

Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study by ESCUDIER, Bernard, PORTA, Camillo, SEVIN, Emmanuel, NEGRIER, Sylvie, KHAN, Sadya, DIAZ, Jose, REDHU, Suman, MEHMUD, Faisal, CELLA, David, BONO, Petri, POWLES, Thomas, EISEN, Tim, STERNBERG, Cora N, GSCHWEND, Jürgen E, DE GIORGI, Ugo, PARIKH, Omi, HAWKINS, Robert

“…Patient-reported outcomes may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted therapies…”
Get full text

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy by James, Nicholas D, de Bono, Johann S, Spears, Melissa R, Clarke, Noel W, Mason, Malcolm D, Dearnaley, David P, Ritchie, Alastair W.S, Amos, Claire L, Gilson, Clare, Jones, Rob J, Matheson, David, Millman, Robin, Attard, Gerhardt, Chowdhury, Simon, Cross, William R, Gillessen, Silke, Parker, Christopher C, Russell, J. Martin, Berthold, Dominik R, Brawley, Chris, Adab, Fawzi, Aung, San, Birtle, Alison J, Bowen, Jo, Brock, Susannah, Chakraborti, Prabir, Ferguson, Catherine, Gale, Joanna, Gray, Emma, Hingorani, Mohan, Hoskin, Peter J, Lester, Jason F, Malik, Zafar I, McKinna, Fiona, McPhail, Neil, Money-Kyrle, Julian, O’Sullivan, Joe, Parikh, Omi, Protheroe, Andrew, Robinson, Angus, Srihari, Narayanan N, Thomas, Carys, Wagstaff, John, Wylie, James, Zarkar, Anjali, Parmar, Mahesh K.B, Sydes, Matthew R

“…The addition of abiraterone and prednisolone to standard androgen-deprivation therapy as the first treatment for patients with locally advanced or metastatic…”
Get full text

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial by Motzer, Robert J, Russo, Paul, Grünwald, Viktor, Tomita, Yoshihiko, Zurawski, Bogdan, Parikh, Omi, Buti, Sebastiano, Barthélémy, Philippe, Goh, Jeffrey C, Ye, Dingwei, Lingua, Alejo, Lattouf, Jean-Baptiste, Albigès, Laurence, George, Saby, Shuch, Brian, Sosman, Jeffrey, Staehler, Michael, Vázquez Estévez, Sergio, Simsek, Burcin, Spiridigliozzi, Julia, Chudnovsky, Aleksander, Bex, Axel

“…Effective adjuvant therapy for patients with resected localised renal cell carcinoma represents an unmet need, with surveillance being the standard of care. We…”
Get full text

A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma by Crabb, Simon J, Hussain, Syed, Soulis, Eileen, Hinsley, Samantha, Dempsey, Laura, Trevethan, Avril, Song, YeePei, Barber, Jim, Frew, John, Gale, Joanna, Faust, Guy, Brock, Susannah, McGovern, Ursula, Parikh, Omi, Enting, Deborah, Sundar, Santhanam, Ratnayake, Gihan, Lees, Kathryn, Birtle, Alison J, Powles, Thomas, Jones, Robert J

“…A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy…”
Get full text

Multi-centre prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) or enzalutamide (ENZ): The ACE study by Bahl, Amit, Challapalli, Amarnath, Birtle, Alison Jane, Foulstone, Emily, Renninson, Emily, Ashurst, Lauren, Bravo, Alicia, Parikh, Omi, Sankey, Peter, Maund, Isabella, Srinivasan, Rajaguru, Das, Prantik, Ratnayake, Gihan, Gray, Emma, Varughese, Mohini, Tran, Anna, Clarke, Noel, McGovern, Ursula, Needleman, Sarah, White, Paul

“…20 Background: AA and ENZ are both approved for the treatment of mCRPC. Understanding the early impact of these treatments on various domains of cognitive…”
Get full text

Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK by Heseltine, Jonathan, Allison, Jennifer, Wong, Sam, Prasad, Kellati, Wong, Helen, Oong, Zhu, Charnley, Natalie, Law, Andrea, Parikh, Omi, Pillai, Manon Rhys, Waddell, Tom, Griffiths, Richard, Chow, Shien

“…Abstract only 335 Background: The TIVO-1 study demonstrated improved PFS in mRCC patients (pts) undergoing 1L treatment with T compared with sorafenib. We…”
Get full text

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial by Parker, Chris C, James, Nicholas D, Brawley, Christopher D, Clarke, Noel W, Ali, Adnan, Amos, Claire L, Attard, Gerhardt, Chowdhury, Simon, Cook, Adrian, Cross, William, Dearnaley, David P, Douis, Hassan, Gilbert, Duncan C, Gilson, Clare, Gillessen, Silke, Hoyle, Alex, Jones, Rob J, Langley, Ruth E, Malik, Zafar I, Mason, Malcolm D, Matheson, David, Millman, Robin, Rauchenberger, Mary, Rush, Hannah, Russell, J Martin, Sweeney, Hannah, Bahl, Amit, Birtle, Alison, Capaldi, Lisa, Din, Omar, Ford, Daniel, Gale, Joanna, Henry, Ann, Hoskin, Peter, Kagzi, Mohammed, Lydon, Anna, O'Sullivan, Joe M, Paisey, Sangeeta A, Parikh, Omi, Pudney, Delia, Ramani, Vijay, Robson, Peter, Srihari, Narayanan Nair, Tanguay, Jacob, Parmar, Mahesh K B, Sydes, Matthew R

“…STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate cancer with…”
Get full text